Index RUT P/E - EPS (ttm) -1.10 Insider Own 48.58% Shs Outstand 102.20M Perf Week 1.78%
Market Cap 794.00M Forward P/E - EPS next Y -1.44 Insider Trans -0.37% Shs Float 54.88M Perf Month -3.38%
Income -101.74M PEG - EPS next Q -0.31 Inst Own 52.43% Short Float 19.37% Perf Quarter -35.47%
Sales 36.53M P/S 21.74 EPS this Y -19.44% Inst Trans -2.66% Short Ratio 17.71 Perf Half Y 1.09%
Book/sh 2.48 P/B 3.00 EPS next Y -11.30% ROA -23.44% Short Interest 10.63M Perf Year 127.52%
Cash/sh 3.16 P/C 2.35 EPS next 5Y - ROE -40.49% 52W Range 2.47 - 13.03 Perf YTD -24.85%
Dividend Est. - P/FCF - EPS past 5Y - ROI -35.09% 52W High -42.90% Beta 0.87
Dividend TTM - Quick Ratio 7.54 Sales past 5Y 132.62% Gross Margin 88.51% 52W Low 201.21% ATR (14) 0.44
Dividend Ex-Date - Current Ratio 7.54 EPS Y/Y TTM 10.85% Oper. Margin -312.57% RSI (14) 40.16 Volatility 5.29% 5.55%
Employees 140 Debt/Eq 0.15 Sales Y/Y TTM 46.93% Profit Margin -278.54% Recom 1.12 Target Price 17.57
Option/Short Yes / Yes LT Debt/Eq 0.15 EPS Q/Q 4.21% Payout - Rel Volume 0.50 Prev Close 7.33
Sales Surprise -34.12% EPS Surprise -16.79% Sales Q/Q -15.29% Earnings Mar 18 BMO Avg Volume 600.29K Price 7.44
SMA20 -1.04% SMA50 -18.64% SMA200 -12.87% Trades
Volume 301,906 Change 1.50%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-04-24 Initiated Cantor Fitzgerald
Overweight
Feb-12-24 Initiated Piper Sandler
Overweight
$18
Dec-08-23 Initiated B. Riley Securities
Buy
$16
Oct-20-22 Upgrade H.C. Wainwright
Neutral → Buy
$10
Sep-20-21 Initiated SVB Leerink
Outperform
$25
Apr-01-24 04:48PM
Mar-20-24 05:31AM
Mar-18-24 02:52PM
08:10AM
07:00AM
05:20PM
Loading…
Mar-17-24 05:20PM
Mar-06-24 07:00AM
Mar-05-24 04:47PM
Feb-07-24 08:55AM
Jan-31-24 07:00AM
Jan-05-24 04:05PM
Jan-04-24 02:47AM
Jan-03-24 07:00AM
Nov-13-23 07:00AM
Nov-08-23 03:12PM
07:00AM
Loading…
07:00AM
Nov-07-23 07:00AM
Oct-10-23 11:28AM
Oct-09-23 08:50AM
Sep-18-23 07:00AM
Sep-06-23 07:00AM
Sep-05-23 07:00AM
Aug-29-23 05:08PM
Aug-28-23 07:00AM
Aug-10-23 07:00AM
Aug-07-23 07:00AM
Jul-24-23 07:00AM
Jul-10-23 07:00AM
Jun-01-23 07:00AM
May-09-23 07:00AM
04:30PM
Loading…
Apr-18-23 04:30PM
Apr-03-23 07:00AM
Mar-27-23 07:00AM
Mar-14-23 08:11PM
Mar-10-23 10:15PM
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-02-23 07:00AM
Jan-25-23 07:00AM
Dec-15-22 07:00AM
Nov-10-22 07:00AM
Nov-07-22 07:00AM
Oct-19-22 07:00AM
Oct-05-22 08:10AM
Sep-06-22 07:00AM
Aug-13-22 08:27AM
Aug-10-22 07:00AM
Aug-02-22 07:00AM
Jun-27-22 07:00AM
Jun-20-22 07:26AM
Jun-08-22 07:00AM
May-11-22 07:00AM
May-09-22 07:00AM
Apr-19-22 07:22AM
Mar-28-22 07:00AM
Mar-08-22 04:57PM
Mar-03-22 09:41AM
Feb-28-22 07:00AM
Feb-02-22 07:00AM
Jan-24-22 07:00AM
Jan-11-22 09:37AM
Dec-21-21 06:38PM
Nov-11-21 07:00AM
Nov-10-21 10:42AM
Nov-09-21 07:00AM
Nov-01-21 07:00AM
Sep-30-21 04:31PM
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Third Rock Ventures IV, L.P. 10% Owner Feb 20 '24 Sale 12.00 162,500 1,950,000 19,201,475 Feb 21 05:52 PM Weber Barbara Chief Executive Officer Feb 07 '24 Sale 12.62 4,457 56,246 1,535,167 Feb 08 09:14 PM Crystal Adam See Remarks Feb 07 '24 Sale 12.62 4,083 51,527 119,478 Feb 08 09:04 PM Beckman Daniella Chief Financial Officer Feb 07 '24 Sale 12.62 1,817 22,930 132,397 Feb 08 09:08 PM Barry Douglas General Counsel Feb 07 '24 Sale 12.62 1,354 17,087 43,981 Feb 08 09:09 PM Weber Barbara Chief Executive Officer Feb 06 '24 Sale 12.56 4,681 58,806 1,539,624 Feb 08 09:14 PM Crystal Adam See Remarks Feb 06 '24 Sale 12.56 4,288 53,868 123,561 Feb 08 09:04 PM Beckman Daniella Chief Financial Officer Feb 06 '24 Sale 12.56 1,908 23,969 134,214 Feb 08 09:08 PM Barry Douglas General Counsel Feb 06 '24 Sale 12.56 1,422 17,864 45,335 Feb 08 09:09 PM Crystal Adam See Remarks Nov 01 '23 Sale 8.39 7,507 62,994 81,250 Nov 02 04:49 PM Boxer Capital, LLC Oct 16 '23 Buy 6.84 500,000 3,420,000 8,198,642 Oct 17 06:04 PM Boxer Capital, LLC Oct 13 '23 Buy 7.07 750,000 5,302,500 7,698,642 Oct 17 06:04 PM Boxer Capital, LLC Oct 09 '23 Sale 9.97 175,000 1,744,750 6,948,642 Oct 11 09:22 PM Boxer Capital, LLC Oct 09 '23 Sale 9.91 50,000 495,500 693,524 Oct 11 09:22 PM Boxer Capital, LLC Aug 11 '23 Buy 5.15 475,000 2,446,250 743,542 Aug 15 09:34 PM
Index RUT P/E - EPS (ttm) -3.77 Insider Own 17.12% Shs Outstand 164.67M Perf Week 2.98%
Market Cap 5.92B Forward P/E - EPS next Y -3.41 Insider Trans -0.49% Shs Float 136.49M Perf Month 13.37%
Income -436.37M PEG - EPS next Q -0.75 Inst Own 79.15% Short Float 9.15% Perf Quarter 29.59%
Sales 11.58M P/S 511.42 EPS this Y 17.83% Inst Trans 8.22% Short Ratio 8.57 Perf Half Y 79.71%
Book/sh 11.09 P/B 3.24 EPS next Y -7.55% ROA -29.82% Short Interest 12.49M Perf Year 58.48%
Cash/sh 11.25 P/C 3.20 EPS next 5Y - ROE -34.75% 52W Range 15.44 - 38.73 Perf YTD 25.38%
Dividend Est. - P/FCF - EPS past 5Y -36.05% ROI -22.89% 52W High -7.15% Beta 1.48
Dividend TTM - Quick Ratio 13.06 Sales past 5Y 11.11% Gross Margin 19.61% 52W Low 132.90% ATR (14) 1.71
Dividend Ex-Date - Current Ratio 13.06 EPS Y/Y TTM -21.72% Oper. Margin -4207.12% RSI (14) 58.49 Volatility 4.41% 5.28%
Employees 378 Debt/Eq 0.05 Sales Y/Y TTM -67.27% Profit Margin -3768.28% Recom 1.07 Target Price 41.62
Option/Short Yes / Yes LT Debt/Eq 0.04 EPS Q/Q -80.53% Payout - Rel Volume 0.83 Prev Close 35.33
Sales Surprise 11.29% EPS Surprise -33.66% Sales Q/Q -95.16% Earnings Feb 26 AMC Avg Volume 1.46M Price 35.96
SMA20 4.92% SMA50 11.86% SMA200 26.55% Trades
Volume 1,213,241 Change 1.78%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-12-24 Reiterated Needham
Buy
$36 → $46
Apr-10-24 Upgrade Raymond James
Outperform → Strong Buy
$36 → $48
Mar-11-24 Initiated Piper Sandler
Overweight
$43
Jan-05-24 Upgrade BofA Securities
Neutral → Buy
$31 → $34
Jan-04-24 Initiated Wedbush
Outperform
$41
Nov-16-23 Initiated Raymond James
Outperform
$30
Feb-28-23 Upgrade JP Morgan
Neutral → Overweight
$32 → $38
Dec-14-22 Initiated Needham
Buy
$31
Oct-21-22 Initiated Oppenheimer
Outperform
$30
May-20-22 Initiated BofA Securities
Neutral
$24
Mar-01-22 Upgrade Stifel
Hold → Buy
$36 → $26
Sep-23-21 Initiated Stifel
Hold
$34
Aug-12-21 Downgrade Goldman
Buy → Neutral
$49 → $27
May-18-21 Initiated Goldman
Buy
$49
May-21-20 Initiated H.C. Wainwright
Buy
$55
Mar-09-20 Initiated JP Morgan
Neutral
$32
Mar-09-20 Initiated Guggenheim
Buy
$50
Mar-09-20 Initiated Cowen
Outperform
Show Previous Ratings
Apr-09-24 03:34PM
Apr-08-24 11:36AM
Apr-04-24 04:05PM
Mar-28-24 04:05PM
Feb-26-24 05:20PM
04:05PM
Loading…
04:05PM
Feb-20-24 04:05PM
Feb-01-24 04:05PM
Jan-17-24 09:55AM
Jan-04-24 07:00AM
Nov-09-23 09:10AM
Nov-08-23 11:30AM
Nov-07-23 10:14AM
Nov-06-23 05:50PM
04:55PM
04:05PM
Loading…
04:05PM
Nov-01-23 07:00AM
Oct-31-23 04:15PM
Oct-23-23 04:06PM
(Investor's Business Daily) -34.38%
01:48PM
12:04PM
10:07AM
(Investor's Business Daily)
Oct-22-23 02:30AM
Oct-19-23 07:02AM
Oct-16-23 03:19PM
(Investor's Business Daily) +14.08%
09:45AM
Oct-13-23 02:54PM
11:50AM
Oct-04-23 04:05PM
Sep-20-23 07:01AM
07:00AM
Loading…
Sep-19-23 07:00AM
Aug-17-23 04:05PM
Aug-09-23 02:13PM
Aug-08-23 05:50PM
04:05PM
Aug-03-23 04:05PM
Aug-01-23 02:34PM
(American City Business Journals) +20.00%
07:00AM
Jul-06-23 09:59AM
Jun-09-23 08:29AM
Jun-08-23 04:05PM
May-24-23 04:05PM
May-13-23 08:19AM
May-10-23 06:10AM
May-09-23 09:40AM
(Thomson Reuters StreetEvents)
May-08-23 05:25PM
04:02PM
May-03-23 10:00AM
09:55AM
May-01-23 04:05PM
10:01AM
Apr-19-23 07:15AM
Apr-13-23 04:05PM
Apr-06-23 07:00AM
Mar-22-23 11:29AM
Mar-11-23 03:27AM
Mar-07-23 04:02PM
Mar-02-23 09:15PM
Mar-01-23 04:17PM
Feb-27-23 06:25PM
04:05PM
Feb-21-23 04:05PM
Feb-02-23 12:00PM
07:00AM
Jan-23-23 05:31AM
Jan-12-23 03:25AM
Jan-03-23 07:00AM
Dec-31-22 06:15AM
Dec-26-22 08:14AM
Dec-19-22 07:00AM
Dec-08-22 06:19AM
Dec-07-22 04:05PM
Nov-10-22 05:48AM
(Simply Wall St.) +13.34%
Nov-09-22 04:05PM
Nov-07-22 05:55PM
04:05PM
Nov-02-22 10:01AM
09:54AM
Nov-01-22 04:05PM
Oct-24-22 11:07AM
Oct-13-22 11:05AM
Sep-22-22 07:00AM
Sep-01-22 04:05PM
Aug-31-22 04:05PM
Aug-30-22 09:55AM
Aug-12-22 09:55AM
Aug-10-22 08:35AM
Aug-09-22 06:15PM
04:02PM
Jul-28-22 04:02PM
Jul-22-22 04:02PM
Jul-19-22 10:41PM
04:01PM
07:16AM
Jul-13-22 07:00AM
Jun-28-22 07:00AM
Jun-24-22 09:42AM
Jun-09-22 04:02PM
May-11-22 06:22AM
May-09-22 05:35PM
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Patel Sushil Director Apr 10 '24 Option Exercise 16.80 2,155 36,204 17,855 Apr 12 04:23 PM GOLDSMITH MARK A See Remarks Apr 10 '24 Sale 35.33 10,000 353,346 30,424 Apr 12 08:08 PM GOLDSMITH MARK A See Remarks Apr 10 '24 Sale 35.48 7,500 266,122 452,879 Apr 12 08:08 PM Patel Sushil Director Apr 10 '24 Sale 37.00 2,155 79,735 15,700 Apr 12 04:23 PM Cislini Jeff General Counsel Mar 27 '24 Sale 30.99 1,500 46,481 54,374 Mar 28 04:11 PM GOLDSMITH MARK A See Remarks Mar 18 '24 Sale 31.58 5,788 182,804 460,379 Mar 20 04:44 PM Horn Margaret A Chief Operating Officer Mar 18 '24 Sale 31.58 2,914 92,033 139,553 Mar 20 04:44 PM Kelsey Stephen Michael See Remarks Mar 18 '24 Sale 31.58 2,123 67,051 270,909 Mar 20 04:45 PM Anders Jack Chief Financial Officer Mar 18 '24 Sale 31.58 1,261 39,826 101,959 Mar 20 04:43 PM Cislini Jeff General Counsel Mar 18 '24 Sale 31.58 1,252 39,542 55,874 Mar 20 04:45 PM Horn Margaret A Chief Operating Officer Mar 12 '24 Option Exercise 4.09 7,936 32,458 150,403 Mar 13 04:32 PM Horn Margaret A Chief Operating Officer Mar 12 '24 Sale 34.07 7,936 270,345 142,467 Mar 13 04:32 PM Horn Margaret A Chief Operating Officer Mar 11 '24 Option Exercise 4.09 15,735 64,356 158,202 Mar 13 04:32 PM Horn Margaret A Chief Operating Officer Mar 11 '24 Sale 34.02 15,735 535,306 142,467 Mar 13 04:32 PM Cislini Jeff General Counsel Jan 22 '24 Sale 27.00 1,500 40,500 36,126 Jan 24 04:12 PM Kelsey Stephen Michael See Remarks Jan 08 '24 Sale 29.01 3,337 96,809 221,632 Jan 10 04:26 PM Kelsey Stephen Michael See Remarks Jan 02 '24 Sale 29.10 13,330 387,884 224,969 Jan 04 04:06 PM Kelsey Stephen Michael See Remarks Dec 27 '23 Sale 29.01 33,334 966,996 238,299 Dec 29 04:14 PM GOLDSMITH MARK A See Remarks Dec 18 '23 Sale 25.90 8,165 211,488 376,167 Dec 20 05:08 PM Horn Margaret A Chief Operating Officer Dec 18 '23 Sale 25.90 2,993 77,524 101,467 Dec 19 07:30 PM Kelsey Stephen Michael See Remarks Dec 18 '23 Sale 25.90 2,088 54,083 271,633 Dec 20 05:07 PM Anders Jack Chief Financial Officer Dec 18 '23 Sale 25.90 1,775 45,976 76,416 Dec 20 05:10 PM Cislini Jeff General Counsel Dec 18 '23 Sale 25.90 1,229 31,833 37,284 Dec 20 05:08 PM Horn Margaret A Chief Operating Officer Dec 15 '23 Option Exercise 4.09 5,000 20,450 109,460 Dec 19 07:30 PM Horn Margaret A Chief Operating Officer Dec 15 '23 Sale 26.64 5,000 133,183 104,460 Dec 19 07:30 PM Horn Margaret A Chief Operating Officer Dec 06 '23 Option Exercise 4.09 5,000 20,450 109,460 Dec 08 04:08 PM Horn Margaret A Chief Operating Officer Dec 06 '23 Sale 25.00 5,000 125,000 104,460 Dec 08 04:08 PM Cislini Jeff General Counsel Nov 20 '23 Sale 21.70 1,500 32,545 38,513 Nov 20 06:24 PM Horn Margaret A Chief Operating Officer Oct 25 '23 Option Exercise 0.54 7,500 4,050 104,460 Oct 25 06:20 PM GOLDSMITH MARK A See Remarks Oct 24 '23 Option Exercise 0.49 35,000 17,150 384,332 Oct 24 07:21 PM Anders Jack Chief Financial Officer Oct 23 '23 Option Exercise 2.98 24,524 72,967 78,191 Oct 23 06:01 PM Horn Margaret A Chief Operating Officer Oct 16 '23 Option Exercise 4.09 25,000 102,250 121,960 Oct 18 04:23 PM Horn Margaret A Chief Operating Officer Oct 16 '23 Sale 33.95 25,000 848,806 96,960 Oct 18 04:23 PM Kelsey Stephen Michael See Remarks Oct 11 '23 Sale 29.05 16,667 484,130 273,721 Oct 13 04:20 PM Cislini Jeff General Counsel Sep 28 '23 Sale 28.20 2,000 56,394 40,013 Oct 02 04:12 PM GOLDSMITH MARK A See Remarks Sep 18 '23 Sale 31.31 8,054 252,175 349,332 Sep 20 04:12 PM Horn Margaret A Chief Operating Officer Sep 18 '23 Sale 31.31 2,514 78,715 96,960 Sep 19 04:17 PM Kelsey Stephen Michael See Remarks Sep 18 '23 Sale 31.31 2,060 64,500 290,388 Sep 20 04:13 PM Anders Jack Chief Financial Officer Sep 18 '23 Sale 31.31 1,427 44,680 53,667 Sep 20 04:11 PM Cislini Jeff General Counsel Sep 18 '23 Sale 31.31 1,214 38,011 42,013 Sep 20 04:11 PM Horn Margaret A Chief Operating Officer Sep 15 '23 Option Exercise 4.09 5,000 20,450 104,474 Sep 19 04:17 PM Horn Margaret A Chief Operating Officer Sep 15 '23 Sale 32.08 5,000 160,408 99,474 Sep 19 04:17 PM Weber Barbara Director Sep 01 '23 Option Exercise 3.80 15,000 57,037 30,825 Sep 06 08:03 PM Anders Jack Chief Financial Officer Sep 01 '23 Option Exercise 2.68 20,000 53,600 75,094 Sep 06 08:02 PM GOLDSMITH MARK A See Remarks Sep 01 '23 Option Exercise 0.77 30,000 23,164 387,386 Sep 06 08:05 PM GOLDSMITH MARK A See Remarks Sep 01 '23 Sale 35.05 30,000 1,051,563 357,386 Sep 06 08:05 PM Anders Jack Chief Financial Officer Sep 01 '23 Sale 35.05 20,000 701,092 55,094 Sep 06 08:02 PM Weber Barbara Director Sep 01 '23 Sale 35.07 15,000 526,000 15,825 Sep 06 08:03 PM GOLDSMITH MARK A See Remarks Sep 01 '23 Sale 35.04 10,000 350,410 35,424 Sep 06 08:05 PM Horn Margaret A Chief Operating Officer Aug 31 '23 Option Exercise 4.09 10,000 40,900 109,474 Sep 01 04:16 PM Horn Margaret A Chief Operating Officer Aug 31 '23 Sale 34.05 10,000 340,458 99,474 Sep 01 04:16 PM Horn Margaret A Chief Operating Officer Aug 15 '23 Option Exercise 4.09 5,000 20,450 104,474 Aug 17 04:17 PM Horn Margaret A Chief Operating Officer Aug 15 '23 Sale 30.53 5,000 152,632 99,474 Aug 17 04:17 PM Kelsey Stephen Michael See Remarks Aug 02 '23 Sale 32.40 16,666 539,978 292,448 Aug 03 04:17 PM Kelsey Stephen Michael See Remarks Aug 01 '23 Sale 29.19 16,666 486,502 309,114 Aug 03 04:17 PM Cislini Jeff General Counsel Jul 31 '23 Sale 26.02 1,500 39,030 43,227 Aug 01 06:23 PM Kelsey Stephen Michael See Remarks Jun 20 '23 Sale 24.89 2,102 52,321 325,780 Jun 22 04:26 PM Horn Margaret A Chief Operating Officer Jun 20 '23 Sale 24.89 2,102 52,321 99,474 Jun 22 04:26 PM Cislini Jeff General Counsel Jun 20 '23 Sale 25.14 1,239 31,148 44,727 Jun 22 04:24 PM Anders Jack Chief Financial Officer Jun 20 '23 Sale 24.89 1,249 31,089 55,094 Jun 22 04:25 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
